At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 16 enrolled
Drug / intervention
Regulatory T-cell enriched infusionbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I Trial of Donor Regulatory T-cells for Steroid-Refractory Chronic Graft-versus-Host-Disease in Patients Who do Not Obtain Complete Remission With Ruxolitinib
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla·interventional·Posted Sep 25, 2018·Updated May 23, 2022
In Brief
A Phase 1 clinical trial evaluating Regulatory T-cell enriched infusion for Chronic Graft vs Host Disease. Completed, enrolled 16 participants across 1 site.
Detailed Summary
A Phase I Trial of Donor Regulatory T-cells for Steroid-Refractory Chronic Graft-versus-Host-Disease in patients who do not obtain complete remission with ruxolitinib
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Graft vs Host Disease
CountriesSpain
Collaborators--
Timeline
Phase 1CompletedFinished
20192020202120222023202420252026
First PostedSep 2018
Enrollment StartSep 2018
Primary CompletionMar 2022
TodayJul 2026
First PostedSep 25, 2018
Enrollment StartSep 25, 2018
Primary CompletionMar 24, 2022
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 7.8 years ago
Interventions
Regulatory T-cell enriched infusionbiological
Enrichment of CD25hi regulatory T cells from CD8 and/or CD19 pre-depleted leukapheresis products.